Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat

Psychopharmacology

Volumn 215, Issue 3, 2011, Pages 513-526

  Keller, Courtney M ^a   Salvatore, Michael F ^a   Pruett, Brandon S ^a   Guerin, Glenn F ^a   Goeders, Nicholas E ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Dopamine; Dopamine transporter; Methamphetamine; Nigrostriatal; Nucleus accumbens; Signal transduction; Striatum; Substantia nigra; Tyrosine hydroxylase; Ventral tegmental area; Vesicular monoamine transporter

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; DOPAMINE UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOPAMINE METABOLISM; DRUG ABUSE; DRUG DOSE ESCALATION; MALE; MESOACCUMBENS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; TISSUE DISTRIBUTION; VENTRAL TEGMENTUM; ANIMAL; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; METABOLISM; TIME; WISTAR RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 80052345891     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2301-9     Document Type: Article

References (69)

1. Argilli E, Sibley DR, Malenka RC, England PM, Bonci A (2008) Mechanism and time course of cocaine-induced long-term potentiation in the ventral tegmental area. J Neurosci 28: 9092-9100
2. Bevilaqua LRM, Graham ME, Dunkley PR, von Nagy-Felsobuki EI, Dickson PW (2001) Phosphorylation of Ser19 alters the conformation of tyrosine hydroxylase to increase the rate of phosphorylation of ser40. J Biol Chem 276: 40111-40416
3. Boger HA, Middaugh LD, Patrick KS, Ramamoorthy S, Denehy ED, Zhu H, Pacchioni AM, Granholm AC, McGinty JF (2007) Longterm consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci 27: 8816-8825 (Pubitemid 47292766)
4. Cadet JL, McCoy MT, Cai NS, Krasnova IN, Ladenheim B, Beauvais G, Wilson N, Wood W, Becker KG, Hodges AB (2009) Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS ONE 4: e7812
5. Callaghan RC, Cunningham JK, Sajeev G, Kish SJ (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 25(14): 2333-2339
6. Cass WA, Manning MW (1999) Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 19: 7653-7660 (Pubitemid 29404621)
7. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL et al (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27: 8138-8148 (Pubitemid 47173329)
8. Caudle WM, Colebrooke RE, Emson PC, Miller GW (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 31: 303-308
9. Chu P-W, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE (2010) Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. J Neurochem 115: 325-332
10. Cruz-Muros I, Afonso-Oramas D, Abreu P, Rodriguez M, Gonzalez MC, Gonzalez-Hernandez T (2008) Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging. Neurobiol Aging 29: 1702-1711
11. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2007) Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol 559: 46-54 (Pubitemid 46274645)
12. Dobbs LK, Mark GP (2008) Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. Neuroscience 156: 700-711
13. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91: 1025-1043 (Pubitemid 39587442)
14. Feltenstein MW, See RE (2008) The neurocircuitry of addiction: an overview. Br J Pharmacol 154: 261-274 (Pubitemid 351670601)
15. Galloway GP, Singleton EG (2009) How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: craving and ongoing methamphetamine use. Subst Abuse 1: 63-79
16. Garwood ER, Bekele W, McCulloch CE, Christine CW (2006) Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 27: 1003-1006 (Pubitemid 44838951)
17. Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, DeFelice LJ, Khoshbouei H (2009) Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem 284: 2978-2989
18. Guilarte TR (2001) Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22: 725-731 (Pubitemid 34075630)
19. Haycock JW (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J Biol Chem 265: 11682-11691
20. Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve terminals: multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem 266: 5650-5657
21. Haughey HM, Fleckenstein AE, Hanson GR (1999) Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem 72: 661-668 (Pubitemid 29055228)
22. Jedynak JP, Ali SF, Haycock JW, Hope BT (2002) Acute administration of cocaine regulates the phosphorylation of serine-19, -31, and -40 in tyrosine hydroxylase. J Neurochem 82: 382-388 (Pubitemid 34774629)
23. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci 95: 4029-4034 (Pubitemid 28173248)
24. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238
25. Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C et al (2010) Methamphetamine self-administration in associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS ONE 5: e8790
26. Kuczenski R, Segal DS, Melega WP, Lacan G, McCunney SJ (2009) Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. Neuropsychopharmacology 34: 2430-2441
27. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22: 8951-8960 (Pubitemid 35379065)
28. Lavicky J, Dunn AJ (1993) Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem 60: 602-612 (Pubitemid 23030957)
29. Letchworth SR, Nader MA, Smith HR, Friedman DP, Porrino LJ (2001) Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J Neurosci 21: 2799-2807 (Pubitemid 32298221)
30. Lindgren N, Goiny M, Herrera-Marschitz M, Haycock JW, Hokfelt T, Fisone G (2002) Activation of extracellular signal-regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain. Eur J Neurosci 15: 769-773 (Pubitemid 35471943)
31. Lu L, Wang X, Wu P, Xu C, Zhao M, Morales M, Harvey BK, Hoffer BJ, Shaham Y (2009) Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psych 66: 137-145
32. Madden LJ, Flynn CT, Zandonatti MA, May M, Parsons LH, Katner SN et al (2005) Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30: 350-359 (Pubitemid 40129486)
33. Masserano JM, Baker I, Natsukari N, Wyatt RJ (1996) Chronic cocaine administration increases tyrosine hydroxylase activity in the ventral tegmental area through glutaminergic- and dopaminergic D2-receptor mechanisms. Neurosci Lett 217: 73-76 (Pubitemid 26358806)
34. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN- 35, 428. J Neurosci 18: 8417-8422 (Pubitemid 28465016)
35. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008) Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91-100
36. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J 20: 571-573 (Pubitemid 46671253)
37. Mizoguchi H, Yamada K, Mizuno M, Mizuno T, Nitta A, Noda Y, Nabeshima T (2004) Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol Pharm 65: 1293-1301 (Pubitemid 38543500)
38. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ et al (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 12: 363-370 (Pubitemid 38160321)
39. Nimitvalai S, Brodie MS (2010) Reversal of prolonged dopamine inhibition of dopaminergic neurons of the ventral tegmental area. J Pharmacol Exp Ther 333: 555-563
40. Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel WM (1996) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16: 4135-4145 (Pubitemid 26192409)
41. O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270: 741-751 (Pubitemid 24271391)
42. Pruett BS, Salvatore MF (2010) GFR a-1 receptor expression in the aging nigrostriatal and mesoaccumbens pathways. J Neurochem 115: 707-715
43. Riviere GJ, Byrnes KA, Gentry WB, Owens SM (1999) Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291: 1220-1226
44. Rossato JI, Bevilaqua LRM, Izquierdo I, Medina JH, Cammarota M (2009) Dopamine controls persistence of long-term memory storage. Science 325: 1017-1020
45. Salvatore MF, Garcia-Espana A, Goldstein M, Deutch AY, Haycock JW (2000) Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J Neurochem 75: 225-232 (Pubitemid 30418187)
46. Salvatore MF, Waymire JC, Haycock JW (2001) Depolarizationstimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 79: 349-360 (Pubitemid 32988951)
47. Salvatore MF, Zhang JL, Large DM, Wilson PE, Gash CR, Thomas TC et al (2004) Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem 90: 245-254 (Pubitemid 38879178)
48. Salvatore MF, Gerhardt GA, Dayton RD, Klein RL, Stanford JA (2009a) Bilateral effects of unilateral GDNF administration on dopamine- and GABA-regulating proteins in the rat nigrostriatal system. Exp Neurol 219: 197-207
49. Salvatore MF, Pruett BS, Spann SL, Dempsey C (2009b) Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS ONE 4: e8466
50. Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, Kalivas PW (2009) Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter in the prefrontal cortex and dorsal striatum not accompanied by marked dopaminergic depletion. J Pharmacol Exp Ther 331: 555-562
51. Self DW (2004) Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology 47: 242-255 (Pubitemid 39298268)
52. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2003) Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28: 1730-1740 (Pubitemid 41070838)
53. Shepard JD, Chuang DT, Shaham Y, Morales M (2006) Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology 185: 505-513
54. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 738: 172-175 (Pubitemid 26379662)
55. Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 105: 605-616 (Pubitemid 351562714)
56. Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2009) Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109: 1745-1755
57. Valjent E, Corvol J-C, Pages C, Besson M-J, Maldonado R, Caboche J (2000) Involvement of the extracellular signal-regulated kinase cascade for cocaine rewarding properties. J Neurosci 20: 8701-8709
58. Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D et al (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382 (Pubitemid 32205193)
59. Volz TJ, Hanson GR, Fleckenstein AE (2007) The role of the plasmalemmal dopamine and vesicular monamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101: 883-888 (Pubitemid 46683868)
60. Wallace TL, Gudelsky GA, Vorhees CV (1999) Methamphetamineinduced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. JNeurosci 19: 9141-9148 (Pubitemid 30226734)
61. Wang J, Carnicella S, Ahmadiantehrani S, He D-Y, Barak S, Kharazia V, Hamida SB, Zapata A, Shippenberg TS, Ron D (2010) Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. J Neurosci 30: 14502-14512
62. Waymire JC, Craviso GL, Lichteig K, Johnston JP, Baldwin C, Zigmond RE (1991) Vasoactive intestinal peptide stimulates catecholamine biosynthesis in isolated adrenal chromaffin cells: evidence for a cyclic AMP-dependent phosphorylation and activation of tyrosine hydroxylase. J Neurochem 57: 1313-1324 (Pubitemid 21922758)
63. Weiss F (2005) Neurobiology of craving, conditioned reward and relapse. Curr Op Pharmacol 5: 9-19 (Pubitemid 40124529)
64. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703 (Pubitemid 26191961)
65. Wise RA (1996) Neurobiology of addiction. Curr Op Neurobiol 6: 243-251 (Pubitemid 26168484)
66. Wise RA (2009) Roles for nigrostriatal-not just mesocorticolimbic- dopamine in reward and addiction. Trends Neurosci 32: 517-524
67. Zahniser NR, Sorkin A (2009) Trafficking of dopamine transporters in psychostimulant actions. Sem Cell Dev Biol 20: 411-417
68. Zaman V, Boger HA, Granholm AC, Rohrer B, Moore A, Buhusi M, Gerhardt GA, Hoffer BJ, Middaugh LD (2008) The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior. Eur J Neurosci 28: 1557-1568
69. Zellner MR, Ranaldi R (2010) How conditioned stimuli acquire the ability to activate VTA dopamine cells: a proposed neurobiological component of reward-related learning. Neurosci Behav Rev 34: 769-780